A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma
E. Gortzak(The Netherlands Cancer Institute), Alberto Azzarelli(Fondazione IRCCS Istituto Nazionale dei Tumori), J. Buesa(Hospital Universitario Central de Asturias), V. Bramwell(Ottawa Regional Cancer Foundation), Frits van Coevorden(The Netherlands Cancer Institute), A.N. van Geel(Rotterdam University of Applied Sciences), Adnan Ezzat(King Faisal Specialist Hospital & Research Centre), Armando Santoro(Fondazione IRCCS Istituto Nazionale dei Tumori), J. Wolter Oosterhuis(Rotterdam University of Applied Sciences), M. van Glabbeke(European Organisation for Research and Treatment of Cancer), A. Kirkpatrick(European Organisation for Research and Treatment of Cancer), Jaap Verweij(Rotterdam University of Applied Sciences)
Cited by 378
Abstract
Related Papers
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
|The Lancet|1997|1k